An interventional study of Usual Care and Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS) in Intracerebral Hemorrhage, sponsored by Capital Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.
Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 11th largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2025, is one of 35 with no phase, reaches primary completion later than 22 of the 61 other live ones, and was the 84th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Jiangsu Province (Suqian) Hospital · Sites in China
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Yanyan Gong · Sites in China
Ages 18–85
Beijing Tiantan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 14 · Phase 4 4
First in 2005; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 180 across the 77 interventional studies, 664 across the 46 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 123 have an industry lead sponsor. The 10 most frequent:
Capital Medical University is the lead sponsor of 296 studies on the registry; 90 are open to participants now.
Capital Medical University has 9 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
14 of the studies in Cerebral Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868511Phase 3Beijing Tiantan HospitalNeuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | 2027-03-01 |
| NCT06688162Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S) | 2026-11-30 |
| NCT06688201Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L) | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 123 studies in Cerebral Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine whether minimally invasive soft channel brain hemorrhage evacuation (scMIS), compared to usual care, leads to superior functional recovery as measured by utility-weighted modified Rankin Scale (UW-mRS) scores at 6 months in patients with basal ganglia intracerebral hemorrhage (ICH) of 20 ≤ volume ≤ 30 ml.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults (18 - 80 years) ;
Definite evidence the ICH is secondary to a structural abnormality in the brain (eg arteriovenous malformation, intracranial aneurysm, tumour, trauma, cerebral venous thrombosis) or previous thrombolysis or neurointerventional surgery.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Usual Care
Other: Usual Care
Minimally Invasive Soft Channel Brain Haemorrhage Evacuation(scMIS)
Procedure: Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)
During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
Functional recovery according to UW-mRS assessed at 6 months
Utility weighted modified rankin scale scores is to map functional status (modified Rankin Scale \[mRS\] scores) and health-related quality of life on the European Quality of Life 5-dimensional questionnaire (EQ-5D) to derive utility-weighted (UW) stroke outcome measures.
Time frame: 6 months
Discharge at Day 7 (yes vs. no)
Discharge status will be assessed at Day 7
Time frame: 7 days after randomization
Total length of intensive care unit stay.
The complete length of time a patient is admitted to the intensive care unit (ICU)
Time frame: During hospitalisation up to 6 months after randomization
Ordinal analysis of modified Rankin Scale [mRS] scores at 28 days
Ordinal analysis of modified Rankin Scale \[mRS\] score: 0 =No symptoms at all.1 =No significant disability despite symptoms, able to carry out all usual duties and activities.2 =Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance.3 =Moderate disability requiring some help, but able to walk without Assistance. 4 =Moderate severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance.5 =Severe disability, bedridden incontinent, and requiring constant nursing care and attention.6 =Dead.
Time frame: 28 days after randomization
The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 3-6
Proportion of subjects with modified Rankin Scale \[mRS\] 3-6 at 6 months after randomization
Time frame: 6-months after randomization
The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 3-5
Proportion of subjects with modified Rankin Scale \[mRS\] 3-5 at 6 months after randomization
Time frame: 6-months after randomization
The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 0-6
Modified Rankin Scale \[mRS\] score at 6 months analysed as an ordinal outcome (categories 0 to 6).
Time frame: 6-months after randomization
The following at 6-months: AMC Linear Disability Score(ALDs)
The AMC (Academic Medical Center) Linear Disability Score (ALDs) is a calibrated generic item bank designed to measure physical disability levels in patients. The ALDs is a sensitive and generic scale that encompasses a broader range of activities compared to the Rankin assessment. The key distinction between the ALDs and the Rankin assessment is that the ALDs provides a linear disability score based on patient-reported outcomes, while the Rankin score is an ordinal assessment determined by a rater.
Time frame: 6-months after randomization
The following at 6-months: EuroQoL Group 5-Dimension self-report questionnaire (EQ-5D)
An EQ-5D score, also referred to as an EQ-5D value index or utility, quantifies a person's health status on a scale from 1 (full health) to 0 (equivalent to being dead). Negative values may be assigned to health states considered worse than death.The score is calculated using a formula that applies specific weights to each level in the various dimensions of the EQ-5D, with these weights derived from a value set that includes index values for all possible EQ-5D states.
Time frame: 6-months after randomization
Days of hospitalization
Length of stay in hospital
Time frame: During hospitalisation up to 6 months after randomization
Safety outcomes
Mortality, rebleeding, infections, and other serious adverse events (SAEs) recorded throughout the entire study period.
Time frame: Throughout the entire study period up to 6 months after randomization
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Nov 2026, 22 months after the start.
Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 22 months is below that.
Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.